Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 1.00 |
| ▸ | CCNK | O75909 | 9/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 9/20 | 1.00 |
| ▸ | CDK9 | P50750 | 8/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 8/20 | 1.00 |
| ▸ | CDK1 | P06493 | 8/20 | 1.00 |
| ▸ | CDK7 | P50613 | 6/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 6/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 6/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 6/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 5/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 5/20 | 1.00 |
| ▸ | CDK4 | P11802 | 4/20 | 1.00 |
| ▸ | CCND1 | P24385 | 4/20 | 1.00 |
| ▸ | CCNH | P51946 | 4/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 2/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.82 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13001905 | 1.00 | CDK2 (1.00) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL29644968 | 1.00 | CDK2 (1.00) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL13001902 | 1.00 | CDK2 (1.00) | CDK2CCNKCDK12CDK9CCNE1 | |
| Hydrochloric Acid SCHEMBL21177798 | 0.99 | CDK2 (0.98) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL3690866 | 0.96 | CDK2 (0.92) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL20383014 | 0.91 | CDK2 (0.83) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL19705772 | 0.91 | CDK2 (0.83) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL23683123 | 0.91 | CDK5 (0.82) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL17628573 | 0.90 | CDK2 (1.00) | CDK2CCNKCDK12CDK9CCNE1 | |
| SCHEMBL13001898 | 0.90 | CDK2 (1.00) | CDK2CCNKCDK12CDK9CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| EP-3749670-B1 | 5-ALKYLTHIO-7-[(4-ARYLBENZYL)AMINO]-1(2)H-PYRAZOLO[4,3-D]PYRIMIDINES FOR TREATMENT OF LYMPHOMA | UNIV PALACKEHO (CZ) | 2021-10-06 | — | — | EP | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-10882863-B2 | Compounds for reducing c-Myc in c-Myc overexpressing cancers background | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-01-05 | — | — | US | disclosed |
| EP-3749670-A1 | 5-ALKYLTHIO-7-[(4-ARYLBENZYL)AMINO]-1(2)H-PYRAZOLO[4,3-D]PYRIMIDINES FOR TREATMENT OF LYMPHOMA | Univerzita Palackeho v Olomouci (CZ) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019149295-A1 | 5-ALKYLTHIO-7-[(4-ARYLBENZYL)AMINO]-1(2)H-PYRAZOLO[4,3-D]PYRIMIDINES FOR TREATMENT OF LYMPHOMA | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2019-08-08 | — | — | WO | disclosed |
| EP-2187889-B1 | USE OF PURINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT | CENTRE NAT RECH SCIENT (FR) | 2013-11-06 | — | — | EP | disclosed |
| US-8431583-B2 | Use of purine derivatives for the manufacture of a medicament | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-04-30 | — | — | US | disclosed |
| US-8431583-B2 | Use of purine derivatives for the manufacture of a medicament | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-04-30 | — | — | US | disclosed |
| US-20120149708-A1 | MODULATORS OF VIRAL TRANSCRIPTION, AND METHODS AND COMPOSITIONS THEREWITH | GEORGE MASON UNIVERSITY | 2012-06-14 | — | — | US | disclosed |
| US-20120149708-A1 | MODULATORS OF VIRAL TRANSCRIPTION, AND METHODS AND COMPOSITIONS THEREWITH | GEORGE MASON UNIVERSITY | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | CDK2 2103/4885CCNK 1807/4885CDK12 2122/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CDK2 1489/4885CCNK 2881/4885CDK12 1663/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CDK2 1489/4885CCNK 2881/4885CDK12 1663/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | CDK2 1540/4885CCNK 4146/4885CDK12 1406/4885 |
| US-20120149708-A1 | MODULATORS OF VIRAL TRANSCRIPTION, AND METHODS AND COMPOSITIONS THEREWITH | CDK2, CCNA1, CDK1 | CDK2 1/4885CCNK 14/4885CDK12 55/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | CDK2 1981/4885CCNK 3185/4885CDK12 1562/4885 |
| US-10882863-B2 | Compounds for reducing c-Myc in c-Myc overexpressing cancers background | MYC, MYCBP, BCOR | CDK2 76/4885CCNK 50/4885CDK12 191/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | CDK2 2992/4885CCNK 3719/4885CDK12 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.